Anne S. Tsao, MD of MD Anderson Cancer Center discusses Osimertinib in front-line for EGFR mutated resistance mechanisms and how…
Beth Eaby-Sandy, MSN, CRNP of University of Pennsylvania talks about the serious illness conversation guides and how they can be…
Vassiliki Papadimitrakopoulou, MD of MD Anderson Cancer Center discusses turning cold tumors into hot tumors using agents that address immune…
Anne S. Tsao, MD of MD Anderson Cancer Center discusses mesothelioma trends in 2018 with PrECOG and Ipi Nivo v…
Charles Rudin, MD, PhD of Memorial Sloan Kettering Cancer Center discusses small-cell lung cancer new approaches using immunotherapy. Small-cell lung…
Beth Eaby-Sandy, MSN, CRNP of University of Pennsylvania explains that in patient conversations with loved ones, it’s the best to…
Vassiliki Papadimitrakopoulou, MD of MD Anderson Cancer Center discusses NSCLC checkpoint inhibitors with the combinations of Epacadostat and IL-2 and…
Anne S. Tsao, MD of MD Anderson Cancer Center discusses the new salvage guidelines for mesothelioma, including pembrolizumab & ipilimumab…
Charles Rudin, MD, PhD of Memorial Sloan Kettering Cancer Center discusses Rovalpituzumab Tesirine (Rova-T) a DLL3 target in SCLC. According…
Vassiliki Papadimitrakopoulou, MD of MD Anderson Cancer Center discusses checkpoint inhibitors as first line therapy, pembrolizumab alone and in combination…
Beth Eaby-Sandy, MSN, CRNP of University of Pennsylvania discusses patient conversation management and the “I hope but I worry” phrase.…
Dr. Anne S. Tsao, MD of MD Anderson Cancer Center discusses about their study of LUME-MESO Trial for mesothelioma treatment.…
Charles Rudin, MD, PhD of Memorial Sloan Kettering Cancer Center discusses Osimertinib, its real world toxicity issues and comparison with…
Beth Eaby-Sandy, MSN, CRNP of University of Pennsylvania discusses barriers to patient communication advertising, clinical jargon, and encouraging hopeful messages,…
Vassiliki Papadimitrakopoulou, MD of MD Anderson Cancer Center discusses the 2018 significant NSCLC trials including EMPOWER, KEYNOTE-189, & MYSTIC. This…
Anne S. Tsao, MD of MD Anderson Cancer Center discusses IFCT MAPS trial, the PFS and overall benefit in front-line…
Charles Rudin, MD, PhD of Memorial Sloan Kettering Cancer Center talks about using Osimertinib in first line and possible shift…
Advanced Forms of MPNs are Associated with Chromosomal Abnormalities Involved in Disease Progression
Joshua Bauml, MD of the University of Pennsylvania discusses thoracic oncology in 2018 and the importance of finding better biomarkers.…
Jessica S. Donington, MD of NYU Langone Health discusses pre-operative questions for NSCLC patient treatment. Determining resectable patients from a…
Joshua Bauml, MD of the University of Pennsylvania discusses Osimertinib versus Erlotinib or Gefitinib in the FLAURA Trial. Osimertinib did…
Jessica S. Donington, MD of NYU Langone Health talks about the IASLC Lung Cancer Staging Project and why some factors…
Joshua Bauml, MD of the University of Pennsylvania discusses the next generation sequencing assays that will allow more targeting in…
Jessica S. Donington, MD of NYU Langone Health discusses IASLC lung cancer staging project, important changes and complexities. There are…
Joshua Bauml, MD of the University of Pennsylvania discusses MET Exon 14 Skipping Mutations and Crizotinib. This is an important…
Jessica S. Donington, MD of NYU Langone Health discusses the changes in stage 3A NSCLC using immunotherapy in resectable patients.…
Joshua Bauml, MD of the University of Pennsylvania discusses immunotherapy in lung cancer and the 15-20 percent response rate of…
Jessica S. Donington, MD of NYU Langone Health discusses the surgical dilemmas in the management of locally advanced NSCLC. Dr.…
Joshua Bauml, MD of the University of Pennsylvania discusses the fact that HER2 is over expressed in 60 percent of…
Corey J. Langer, MD, FACP of the University of Pennsylvania discusses how T790M testing is practically standard for EGFR activating…
Corey J. Langer, MD, FACP of the University of Pennsylvania discusses the Pacific Trial overview of Durvalumab in locally advanced…
Laura Jean Bierut, MD of Washington University of Medicine discusses the three levels of smoking cessation. These levels are (1)…
Corey J. Langer, MD, FACP of the University of Pennsylvania discusses his concerns over the PACIFIC Trial data such as…
Laura Jean Bierut, MD of Washington University of Medicine discusses the benefits of E-Cigarettes over combustible cigarettes. First and foremost,…
Corey J. Langer, MD, FACP of the University of Pennsylvania talks about the FLAURA Trial Results and the 8-9 Month…
Laura Jean Bierut, MD of Washington University of Medicine talks about E-Cigarettes and how they may be the greatest public…
Corey J. Langer, MD, FACP of the University of Pennsylvania discusses how in EGFR Activating Mutations, Osimertinib is now the…
Laura Jean Bierut, MD of Washington University of Medicine discusses the two main nicotine responders genetic variations and metabolic enzymes.…
Corey J. Langer, MD, FACP of the University of Pennsylvania talks about 2018 NSCLC trends in prognosticate refinement and the…
Laura Jean Bierut, MD of Washington University of Medicine discusses 400,000 vs 60,000 fatalities per year lung cancer vs opioid…
Tracey L. Evans, MD of the University of Pennsylvania describes what determines using osimertinib in first line treatment. Dr. Evans…
Lyudmila Bazhenova, MD of the University of California, San Diego discusses osimertinib & small cell transformation. There is a very…
Tracey L. Evans, MD of the University of Pennsylvania discusses T790 mutation testing on initial diagnosis. Testing T790M before the…
Lyudmila Bazhenova, MD of the University of California, San Diego discusses management of EGFR-resistant disease and T790M mutations. Management of…
Laura Jean Bierut, MD of Washington University of Medicine talks about when to focus on smoking cessation. There are two…
Tracey L. Evans, MD of the University of Pennsylvania discusses incomplete resections in NSCLC. What to do with incomplete resection,…
Lyudmila Bazhenova, MD of the University of California, San Diego discusses the FLAURA study and improvement in PFS over standard…
Tracey L. Evans, MD of the University of Pennsylvania discusses the impact of immunotherapy in thoracic oncology. Immunotherapy data is…
Lyudmila Bazhenova, MD of the University of California, San Diego discusses T790M mutation and the role of osimertinib in the…
Tracey L. Evans, MD of the University of Pennsylvania describes why Osimertinib is such an important breakthrough in EGFR mutated…
Lyudmila Bazhenova, MD of the University of California, San Diego discusses Metastatic EGFR mutation + Osimertinib in NSCLC first line,…
Dr. Jack West reviews provocative biomarker results on the IMpower150 trial that tested atezolizumab with carboplatin/paclitaxel +/- bevacizumab & revealed…
Patient reported symptom burden and peripheral blood counts among PV patients.
Elderly cancer patients tend to have more complex conditions, and therefore require a strong support system to assist their needs…
With age being the biggest risk factor for cancer, and an ageing population in the UK, the NHS is having…
The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, presented cutting-edge updates in hematology. Discover…
In this exciting interview, Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK,…
The primary thrombocythemia (PT)-1 trial (NCT00175838) comprises a series of three studies, which have been running since 1997 and include…
There was a long period of time without new acute myeloid leukemia (AML) treatments, but now there are a number…
This is an incredibly exciting time for multiple myeloma (MM) research. In this video, some of the most interesting topics…
Dr. Jack West reviews the preliminary clinical results on the IMpower150 trial that tested the value of adding the immune…
The University of Birmingham has partnered with Leuka, NHS Blood and Transplant, and Anthony Nolan to deliver the UKs first…
Understanding the biology of human disease is of the utmost importance to advancing treatment. We are now making excellent headway…
Relapse remains the main obstacle for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic stem cell…
For high-risk acute myeloid leukemia (AML), azacitidine monotherapy is typically utilized. However, there is a low overall response rate and…
The outcome for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) after allogeneic stem cell transplantation remains poor.…
Dr. Susanne Osanto discusses the use of chemotherapy plus androgen deprivation therapy (ADT) for newly diagnosed men with advanced stage…
The Multiple Myeloma Research Foundation (MMRF) has been very active throughout 2017. Here, Daniel Auclair, PhD, of the MMRF, Norwalk,…
Clinical trials and research, regardless of their degree of success, provide useful lessons that can be applied to a range…
The ongoing Phase III ASPIRE trial (NCT01080391) comparing carfilzomib, lenalidomide and dexamethasone (CRd) vs. lenalidomide and dexamethasone (Rd) in patients…
Venetoclax is a BCL-2 inhibitor used in the treatment of chronic lymphocytic lymphoma (CLL), which works through increasing the apoptosis…
Phase I studies investigating a new monoclonal antibody that works through the inhibition of PD-1 have shown similar levels of…
There were many advancements presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA,…
The scientific advances reported at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, were…
The American Society of Hematology (ASH) Annual Meeting and Exposition has become the go-to place for hematology updates for scientists,…
This years American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, presented major advances in hematology,…
The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, showcased the most cutting-edge data…
Athough new molecules have advanced the treatment of Hodgkin lymphoma considerably in recent years, research is still ongoing to achieve…
Although the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, may not have had…
The monitoring of minimal residual disease (MRD) is important in predicting relapse and giving a more sensitive measurement to clinicians…
Although little is currently known about the mechanisms of resistance to venetoclax, researchers are constantly looking for new drugs that…
In chronic lymphocytic leukemia (CLL), venetoclax has established itself as one of the most effective monotherapies in certain contexts. Speaking…
Venetoclax and ibrutinib are two relatively new drugs being used for the treatment of chronic lymphocytic leukemia (CLL), and although…
Social media platforms, such as Twitter, are a staple of the modern world and facilitate communication between people from all…
CAR T-cell therapy has emerged as a highly promising cancer treatment in recent years, with patient’s own cells being modified…
As age increases, the likelihood of a patients with hematological malignancies having further complications and comorbidities increases. Speaking from the…
Immunotherapy has been a primary area of focus in lymphoma research in recent years, with treatments looking to stimulate and…
In this activity, Congress Chair Dr. Morton Coleman and CLL Session Co-Chair Dr. Richard R. Furman discuss highlights of the…
In this Key Insights activity, Congress Chair Dr. Morton Coleman and Lymphoma Session Co-Chair Dr. John Leonard discuss highlights of…
Updates from the highly anticipated Phase III MURANO study (NCT02005471) in relapsed/refractory chronic lymphocytic leukemia (CLL) were presented at the…
In this Key Insights activity, Drs. Morton Coleman and Ruben Niesvizky discuss highlights of the first day of Lymphoma &…
There has historically been less novel agents being tested and moving into the clinic for AML. Now, there has been…
Venetoclax combinations have shown excellent results in chronic lymphocytic leukemia (CLL), but are now, excitingly, displaying fantastic preliminary outcomes in…
Although a key skill of nursing is communication with patients and the multidisciplinary team, ensuring good communication channels within and…
Nursing is a demanding job, with the many responsibilities and patients meaning that nurses are often under considerable time pressure.…
Immunotherapies can come with a range of toxicities that require the appropriate management by acute oncology services. In this interview,…
As novel immunotherapies are introduced into practice, centers need to implement new protocols and educate staff in order to ensure…
Immunotherapies can induce a range of common, as well as rare, side effects. These may be difficult for healthcare professionals…
Collating data and communicating center experiences is essential to ensure that the best standard of care is provided to patients…
Dr. Susanne Osanto discusses the use of chemotherapy plus androgen deprivation therapy (ADT) for newly diagnosed men with advanced stage…
There are many intricacies surrounding the introduction of biosimilars. Here, Simon Cheesman, BPharm, MRPharmS from University College London Hospital (UCLH),…
“During the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium for cancer care pharmacy in Glasgow, UK, Simon Cheesman, BPharm,…
“During the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium for cancer care pharmacy in Glasgow, UK, Simon Cheesman, BPharm,…
“Peter Johnson, BA, MB BChir, MA, MRCP, MD, FRCP from Southampton General Hospital, Southampton, UK, summarises the challenges of cancer…
David Irvine from the Beatson Institute, Glasgow, UK outlines his presentation on cellular advances in hematological oncology given at the…
Having academics who also work in the clinic has a wide range of benefits. In this interview, Naomi Farrington, PhD,…
Elderly cancer patients are likely to have comorbidities and more complex treatment needs, which can result in certain treatments not…
Elderly patients comprise the majority of cancer cases; however, they are often overlooked in many facets of oncology research and…
Pharmacists have an excellent knowledge of drugs and are an essential part of the multidisciplinary healthcare team. Excitingly, they are…
Nurses have a high level of contact with individual patients, which enables them to have a unique perspective on their…
The official recommendations are that patients taking oral systemic anti-cancer therapy (SACT) receive the same level as care as those…
The debate at the UK Oncology Nursing Society (UKONS) Annual Conference 2017 in Harrogate, UK, focused on highlighting the importance…
Dr. Jack West reviews the implications, both encouraging and potentially detrimental, of a recent FDA approval for broad genomic (NGS)…
This is a very exciting time for multiple myeloma (MM) research, with advances in a range of areas from new…
Model systems, including patient specimens and murine organisms, are very important for multiple myeloma (MM) research. Speaking from the Myeloma…
There is a plethora of therapies available for multiple myeloma (MM). In this insightful panel discussion at the Myeloma 2017…
There are currently many exciting novel therapeutics and combination therapies undergoing clinical trials for use in multiple myeloma (MM) patients.…
A key finding of a recent Bloodwise study into the specific needs of hematological cancer patients highlighted the importance of…
Immunotherapy is a growing treatment area for cancer, with a lot of hype in the mainstream media. In this interview,…
Immunotherapy has received a lot of coverage as a revolutionary cancer treatment, in both the medical community and in the…
In recent years, molecular tests have emerged that can help provide information about cancers, such as determining what type of…
Dr. Jack West reviews data on the FDA-approved combination of dabrafenib/trametinib for patients with BRAF V600E mutation-positive advanced NSCLC, as…
It is critical that cancer patients report the side effects of their treatments, whether chemotherapy or immunotherapy, as early as…
With age being the biggest risk factor for cancer, and an ageing population in the UK, the NHS is having…
Recent studies presented at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK have identified multiple…
The data from several recent monoclonal antibody clinical trials for multiple myeloma (MM), which are producing very exciting results, was…
The ongoing TOURMALINE-MM1 study (NCT01564537), a Phase III placebo-controlled clinical trial for relapsed refractory multiple myeloma, has produced very positive…
There have been promising preliminary results from the ongoing ASPIRE study (NCT01080391), a Phase III clinical trial for patients with…
Alberto Rocci, MD from the Central Manchester University Hospital, Manchester, UK discusses the encouraging data from recent clinical trials, looking…
Exciting advances in our knowledge of the epigenetics of multiple myeloma (MM) have recently been made. Speaking at the Myeloma…
The highly anticipated panel discussion on the hot topic of MRD at the Myeloma 2017 meeting in Edinburgh, UK produced…
Fantastic advances in immunotherapy, including CAR T-cells, bispecific antibodies and potential immunotherapy combinations, were presented at the Myeloma 2017 meeting…
The current baseline imaging technology for multiple myeloma (MM) management includes PET and MRI. In this interview, Ravi Vij, MD,…
There is currently a conundrum regarding the differentiation of acute myeloid leukemia and myelodysplastic syndromes. In this interview, Stéphane de…
The utilization of CAR T-cells for the treatment of multiple myeloma (MM) has great potential, with numerous different targets and…
Research into imaging for multiple myeloma (MM) is expanding into an exciting new field, which is explored in this discussion…
The mechanisms of therapy resistance in multiple myeloma (MM) are evolving. This is deliberated in this insightful discussion between Marc…
Inhibitors of exportin (XPO1), a nuclear export chaperone, are currently in early clinical trials for acute myeloid leukemia (AML). Speaking…
There are currently several novel agents that target non-coding RNAs being tested in pre-clinical studies for the treatment of leukemia.…
“There are currently a number of ongoing clinical trials for acute myeloid leukemia (AML) that are targeting nuclear exporters. In…
There are four commonly mutated spliceosome proteins in hematological malignancies. In this interesting interview, recorded at the International Conference on…
New molecules targeting specific gene mutations are showing great potential for precisely treating diseases and lowering the toxicity of treatment.…
Having an understanding of the inherited genetic components that can lead to cancer formation can be of great use to…
Holistic therapies are often viewed unfavorably by the medical community, with many clinicians preferring to solely focus on pharmacological treatments.…
Myeloproliferative neoplasms (MPNs) are complex diseases, with current therapies primarily designed to prevent complications and reduce symptoms. In this insightful…
“Technological advances have allowed for whole genome, exome and transcriptome sequencing of circulating multiple myeloma (MM) cells and cell-free tumor…
It has become apparent in recent years that low levels of ciculating tumor DNA can be detected in multiple myeloma…
The detection of various gene mutations, such as those in Ras and Raf, are important for risk stratification and identifying…
The Myeloma 2017 meeting, held in Edinburgh, UK, saw more focus on epigenetic contributors to multiple myeloma (MM) than ever…
In recent years, researchers have become increasingly aware of the fact that epigenetic alterations can contribute to the formation of…
Although researchers are aware of the fact that epigenetic factors play a significant role in the development of multiple myeloma…
There are several different types of immunotherapy and associated conjunctional therapies currently being studied that have shown some degree of…
Cancer immunotherapy is a very active area of research at the moment, with the potential to treat a cancer long-term…
Drug resistance is a common problem in the treatment of multiple myeloma (MM), either through initial resistance to a drug,…
Clinical trials to determine the efficacy of a drug are costly, particularly when there are many subtypes of a certain…
Immunomodulatory drugs (IMiDs) are a class of drugs including the likes of thalidomide, which are used in the treatment of…
Epigenetic modifications, such as DNA methylation, can lead to or complicate disease, and lead to worse patient outcomes. Speaking from…
The Multiple Myeloma Research Foundation (MMRF) is sponsoring the CoMMpass trial (NCT01454297), which aims to define subsets of multiple myeloma…
Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH), Stéphane…
The IDH2 inhibitor drug, enasidenib has previously only been administered to elderly populations with acute myeloid leukemia. Stéphane de Botton,…
Stéphane de Botton, MD, PhD of the Gustave Roussy Institute, Villejuif, France, discusses the efficiency of differentiation therapies for the…
In this video, Stéphane de Botton, MD, PhD of the Gustave Roussy Institute, Villejuif, France, describes the rapid progression of…
The potential advantage of a therapy compared to its cost is an important factor to consider when approving novel treatments.…
The recent RATIFY study (NCT00651261), which led to the approval of midostaurin for the treatment of FLT3-mutated AML patients, was…
When new drugs are being tested as a treatment for a cancer, they are typically trialled in combination with standard…
In the RATIFY clinical trial (NCT00651261), the FLT3 inhibitor midostaurin plus standard chemotherapy was shown to have an advantage over…
The RATIFY trial (NCT00651261) showed that midostaurin, a FLT3 inhibitor that was a previously ineffective monotherapy for acute myeloid leukemia…
Over recent years, inhibition of excessive FLT3 signalling has been a primary area of research to find an effective targeted…
Acute myeloid leukemia (AML) is a complex disease with many subtypes; treatment can be more effective and efficient if there…
The long-term survival rate of acute myeloid leukemia (AML) patients who have relapsed, or whose disease is progressing, is poor.…
Reflecting upon past research is key to the development of new treatments. In this interview at the International Conference of…
Novel technologies have the potential to allow us to treat more ailments, but often come at the price of new…
New and invigorating methods of tackling acute myeloid leukemia (AML) are being researched at present. In this interview, Saar Gill,…
This is an exciting time for leukemia treatment, with multiple new therapies being approved and various agents on the horizon.…
As innovative research investigating acute myeloid leukemia (AML) progresses, the chances of developing effective treatments against the ailment increase. In…
Eosinophilia is a highly variable disease that can be relatively mild or potentially fatal; it can occur due to primary…
Systemic mastocytosis, though a rare disease, is more common than clinicians may think and diagnosis of the condition can often…
Myeloproliferative Neoplasms (MPNs) carry a risk of complications, such as thrombosis; the degree of risk is influenced in part by…
It is well known that studying larger patient groups produces more robust results in research. Omar Abdel-Wahab, MD, from the…
It is known that spliceosome gene mutations can drive hematological cancers, but there may also be neomorphic mutations at play.…
There is often a lack of communication about the strong evidence linking lifestyle to cancer risk. In this video, Annie…
“Health service personnel are paramount in endorsing and conveying lifestyle messages that reduce the risk of cancer in the public.…
There is extensive and durable evidence supporting the link between lifestyle and cancer recurrence, yet this evidence is not being…
“Lifestyle intervention trials rely heavily on cooperation from the patient group and thus, it is important to effectively engage these…
“As a greater number of people are surviving cancer, this is an exciting time to determine the magnitude of effect…
Dr. Jack West reviews the pros and cons of using osimertinib first line vs. “saving” it as a second line…
Innovative research has begun to create a novel therapy that could potentially treat a variety of malignancies, including acute myeloid…
As research into the different aspects of treating leukemia develops there will be an increase in the number of targeted…
This is an exciting time for acute myeloid leukemia (AML), with the introduction of numerous novel combination therapies and the…
Currently, the majority of therapeutics that target splicing mutations in hematological malignancies are in the early or pre-clinical phases. In…
Mutations can change the function of a protein and thus be the driver of diseases. In this video, Omar Abdel-Wahab,…
Patient advocacy groups can be of great use to patients, giving them means to network with other patients and providing…
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) increasingly appear to be influenced by genetic features, with new research attempting…
In recent years, the medical community has become aware of certain genetic factors that can predispose someone to developing hematological…
Using kinase inhibitors, such as midostaurin, to treat acute myeloid leukemia typically only produces a partial response. Mark Levis, MD,…
The BCL2 inhibitor venetoclax has shown remarkable response rates in elderly acute myeloid leukemia (AML) patients when used in combination…
“In this insightful interview, Mark Levis, MD, PhD, from The Johns Hopkins Hospital, Baltimore, MD, talks about the four primary…
Acute myeloid leukemia (AML) is no longer thought to be just a single disease; thus, each subtype needs to be…
It is still early days for immunotherapeutic strategies. Speaking from the International Conference on Acute Myeloid Leukemia 2017, Estoril, Portugal…
Cancers, such as myeloproliferative neoplasms (MPNs), evolve from repeated mutations; it is unlikely that one mutation alone causes cancer. In…
The discovery of various molecular risk factors for myeloproliferative neoplasms (MPNs) has revolutionized the way in which doctors diagnose these…
Nurses provide a high level of contact to a patient with cancer, which is essential in order to educate them…
An acute oncology service works to manage the unexpected care needs of patients with cancer. In this interview, recorded at…
The use of immunotherapy in the UK as a treatment for cancer has increased over the past decade. In this…
Clinical Nurse Specialists (CNSs) play a key role for a cancer patient, in both performing clinical procedures, and offering psychological…
Conferences can be a fantastic opportunity to network within a certain profession, and get an idea of the challenges that…
Nurses in the UK are highly valued as part of the multidisciplinary health team. However, as Daniel Kelly, PhD, from…
Specialist cancer nurses play a vital role in improving patient care, in both clinical and psychological contexts. In this interview,…
The current baseline imaging technology for multiple myeloma (MM) management includes PET and MRI. In this interview, Ravi Vij, MD,…
Radiological advances are now enabling us to decipher the disease biology of multiple myeloma (MM) in ways that were previously…
There are two new highly promising classes of treatments for multiple myeloma. Speaking from the Myeloma 2017 meeting in Edinburgh,…
Within multiple myeloma (MM), there are biologically different diseases that are distinctly characterized. In this video, Gareth Morgan, MD, FRCP,…
There has been a genome-wide initiative to identify the copy number variants and mutational drivers of multiple myeloma. In this…
Dr. Jack West reviews the results of the ARCHER-1050 trial that showed superior efficacy with dacomitinib vs. gefitinib in EGFR…
A full understanding of the methods available for diagnosis, prognosis and stratification are required in order to choose the optimal…
Although there is a lot of hope and optimism surrounding immunotherapy, Marion Subklewe, MD, of the University of Munich, Munich,…
Cinical trials for acute myeloid leukemia (AML) typically only include relapsed/refractory patients, rather than patients at an earlier stages of…
The use of T-cell engaging antibodies for acute myeloid leukemia (AML) treatment is in the very early stages. In this…
Many variables are involved in selecting the type of treatment that a patient can receive. Speaking from the International Conference…
The widespread accessing of new drugs by HCPs and patients can be a very long process. Currently, venetoclax is in…
“This is an exciting time for new acute myeloid leukemia (AML) therapies, particularly combination treatments. In this video, Marina Konopleva,…
“In this exciting interview, Marina Konopleva, MD, PhD of the MD Anderson Cancer Center, Houston, TX, provides optimistic preliminary results…
Compassion and understanding are two key components within medical care. At the International Conference of Acute Myeloid Leukaemia 2017 in…
New research methods enable a greater understanding of a disease and allow for more personalized medicine to be produced. In…
The effective use of the correct medication can greatly improve the chance of remission for patients with acute myeloid leukemia…
Though women of childbearing age are diagnosed with myeloproliferative neoplasms (MPNs) less frequently than the general population, it is key…
Chronic inflammation is a key hallmark of myeloproliferative neoplasms (MPNs) and is responsible for many of the symptoms that affect…
To effectively treat acute myeloid leukemia (AML) in elderly patients, it is important that therapies for the right demographic are…
Thrombosis is a major risk factor for early mortality in patients with myeloproliferative neoplasms (MPNs), particularly essential thrombocythemia and polycythemia…
As patient awareness and knowledge of disease increases, the way in which doctors provide information to their patients in Spain…
Myeloproliferative neoplasms are complex diseases, with new research constantly updating our understanding of risk factors that may cause the diseases…
For relapsed and elderly acute myeloid leukemia patients, standard treatment is often not good enough. In this interview, Jorge Sierra,…
In this interview, Alessandro Vannucchi, MD, of the University of Florence, Florence, Italy, talks about the new models that doctors…
An advanced age can limit treatment options when tackling leukemia. Speaking from the International Conference on Acute Myeloid Leukaemia 2017,…
As alternatives to chemotherapy are created, the prospect of having treatments with a lower toxicity becomes more tangible. In this…
This is an exciting time for leukemia research, with the latest research using bispecifics revealing positive outcomes for patients. Here,…
The inflammation induced by medication can create challenges when producing novel treatments. In this interview, Prof. John DiPersio, MD, PhD…
It is crucial that drug toxicity is kept as low as possible to improve the quality of life of patients.…
As diseases mutate our knowledge of them increases. In this interview, Prof. John DiPersio, MD, PhD from Washington University School…
This is an exciting time for acute myeloid leukemia (AML) treatment, with multiple new therapies being investigated currently. In this…
Using uniform methods of detection allows for the efficient diagnosis of various ailments. In this interview, Francesco Lo-Coco, MD, from…
As treatment advancements are made, the number of people who cannot be treated effectively is reduced. In this interview, Francesco…
When considering which treatment to prescribe for acute myeloid leukemia (AML), an advanced age is a limiting factor. With recent…
There have been large strides in the treatment of leukemia; however, current methods lack specificity. Speaking from the International Conference…
Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Alfred Hospital and Monash University, Melbourne, Australia discusses how a novel molecule, S64315,…
There is some agreement within the multiple myeloma (MM) community regarding the importance of combination chemotherapy, transplant, personalized therapy and…
The evasion of apoptosis is a hallmark of cancer, which needs to be halted in order to treat malignancies. In…
As novel anticancer drugs undergo clinical trials and enter the market, patients with cancer are experiencing better outcomes and living…
Cancer nurses play a critical role in improving the quality of life and outcomes of patients. In this interview, recorded…